Quick Answer
Revolution Medicines, Inc. reported Diluted EPS of $5.95 per share (loss) for fiscal year 2025.
Revolution Medicines, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$5.95 | -66.2% |
| 2024 | -$3.58 | +7.3% |
| 2023 | -$3.86 | -25.3% |
| 2022 | -$3.08 | -19.8% |
| 2021 | -$2.57 | -27.9% |
| 2020 | -$2.01 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.61 | -71.3% | -22.9% |
| June 30, 2025 | -$1.31 | -61.7% | -15.9% |
| March 31, 2025 | -$1.13 | -61.4% | -20.2% |
| September 30, 2024 | -$0.94 | +5.1% | -16.0% |
| June 30, 2024 | -$0.81 | +12.0% | -15.7% |
| March 31, 2024 | -$0.70 | +2.8% | +29.3% |
| September 30, 2023 | -$0.99 | -13.8% | -7.6% |
| June 30, 2023 | -$0.92 | -12.2% | -27.8% |
- Revolution Medicines, Inc. showed a decrease of -66.2% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, Revolution Medicines, Inc.’s diluted eps has declined by 196.0% (from $2.01 per share (loss) to $5.95 per share (loss)).
- The most recent figure is from Revolution Medicines, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: